Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

University of Chicago Medicine has received a $75 million donation from the AbbVie Foundation to help it build its massive ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

The new facility aims to give residents on the South Side better access to cancer care, while also attracting patients from ...

The University of Chicago Medicine’s incoming cancer center is getting a new name thanks to a $75 million donation from the ...

AbbVie cautions that these forward-looking statements ... but this one gives us a unique opportunity there to go head to head with vedolizumab, especially looking at endoscopic improvement.